In his Latin epic Aeneid, Virgil has the hero Aeneas follow in the footsteps of Odysseus, the hero of Homers Odyssey. Approaching Sicily and Mount Etna, in Book 3 of the Aeneid, Aeneas manages to survive the dangerous Charybdis, and at sundown comes to the land of the Cyclopes, while "near at hand Aetna thunders". The Cyclopes are described as being "in shape and size like Polyphemus ... a hundred other monstrous Cyclopes [who] dwell all along these curved shores and roam the high mountains." After narrowly escaping from Polyphemus, Aeneas tells how, responding to the Cyclops "mighty roar":

the race of the Cyclopes, roused from the woods and high mountains, rush to the harbour and throng the shores. We see them, standing impotent with glaring eye, the Aetnean brotherhood, their heads towering to the sky, a grim conclave: even as when on a mountaintop lofty oaks or cone-clad cypresses stand in mass, a high forest of Jove or grove of Diana. Later, in Book 8 of the same poem, Virgil has the Hesiodic Cyclopes Brontes and Steropes, along with a third Cyclopes which he names Pyracmon, work in an extensive network of caverns stretching from Mount Etna to the Aeolian Islands. As the assistants of the smith-god Vulcan, they forge various items for the gods: thunderbolts for Jupiter, a chariot for Mars, and armor for Minerva:

In the vast cave the Cyclopes were forging iron—Brontes and Steropes and bare-limbed Pyracmon.
History
The synthesis of trospium was described by scientists from Dr. Robert Pfleger Chemische Fabrik GmbH,  Heinz Bertholdt, Robert Pfleger, and Wolfram Schulz, in US. Pat. No. 3,480,626 (the US equivalent to DE119442), and its activity was first published in the literature in 1967.The first regulatory approval was granted in Germany in August 1999 to Madaus AG for Regurin 20 mg Tablets. : 13  Madaus is considered the originator for regulatory filings worldwide. The German filing was recognized throughout Europe under the Mutual Recognition Procedure. : 13 Madaus licensed the US rights to trospium chloride to Interneuron in 1999 and Interneuron ran clinical trials in the US to win FDA approval. Interneuron changed its name to Indevus in 2002 Indevus entered into a partnership with Odyssey Pharmaceuticals, a subsidiary of Pliva, to market the drug in April 2004, and won FDA approval for the drug, which it branded as Sanctura, in May 2004. The approval earned Indevus a milestone payment of $120M from Pliva, which had already paid Indevus $30 million at signing; the market for overactive bladder therapies was estimated to be worth $1.1 billion in 2004. In 2005 Pliva exited the relationship, selling its rights to Esprit Pharma, and in September 2007 Allergan acquired Esprit, and negotiated a new agreement with Indevus under which Allergan would completely take over the US manufacturing, regulatory approvals, and marketing. A month before, Indevus had received FDA approval for an extended release formulation that allowed once a day dosing, Sanctura XR.